References

1. Adane ED, Herald M, Koura F. Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed Staphylococcus aureus Infections. Pharmacotherapy. 2015;35(2):127-139. doi:10.1002/phar.1531

2. Aljutayli A, Thirion DJG, Bonnefois G, Nekka F. Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model-informed precision dosing trial simulations. Clin Transl Sci. 2022;15(4):942-953. doi:10.1111/cts.13210

3. Alqahtani SA, Alsultan AS, Alqattan HM, Eldemerdash A, Albacker TB. Population pharmacokinetic model for vancomycin used in open heart surgery: model-based evaluation of standard dosing regimens. Antimicrob Agents Chemother. 2018;62(7):e00088-18. doi:10.1128/AAC.00088-18

4. Bae SH, Yim DS, Lee H, et al. Application of pharmacometrics in pharmacotherapy: open-source software for vancomycin therapeutic drug management. Pharmaceutics. 2019;11(5):224. doi:10.3390/pharmaceutics11050224

5. Bang J, Kang HI, Lee H, et al. Development of a new pharmacokinetic model for target-concentration controlled infusion of vancomycin in critically ill patients. Clin Exp Pharmacol Physiol. 2022;49(2):202-211. doi:10.1111/1440-1681.13597

6. Belabbas T, Yamada T, Egashira N, et al. Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance. J Infect Chemother. 2023;29(4):391-400. doi:10.1016/j.jiac.2023.01.010

7. Brooks JT, Hughes MSA, Faldasz JD, Keizer RJ, Hughes JH. Leveraging real-world data to create vancomycin population pharmacokinetic models in younger adults and patients with low serum creatinine. JAPhA Pharmacotherapy. 2026;3(1):100026. doi:10.1016/j.japhar.2025.100026

8. Buelga DS, Del Mar Fernandez De Gatta M, Herrera EV, Dominguez-Gil A, García MJ. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother. 2005;49(12):4934-4941. doi:10.1128/AAC.49.12.4934-4941.2005

9. Hughes JH, Keizer RJ. A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT Pharmacometrics Syst Pharmacol. 2021;10(10):1150-1160. doi:10.1002/psp4.12684

10. Bury D, Ter Heine R, Van De Garde EMW, Nijziel MR, Grouls RJ, Deenen MJ. The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults. Eur J Clin Pharmacol. 2019;75(7):921-928. doi:10.1007/s00228-019-02657-6

11. Cheng V, Abdul-Aziz MH, Burrows F, et al. Population pharmacokinetics of vancomycin in critically ill adult patients receiving extracorporeal membrane oxygenation (ASAP ECMO study). Antimicrob Agents Chemother. 2022;66(1):e01377-21. doi:10.1128/AAC.01377-21

12. Chu Y, Luo Y, Ji S, Jiang M, Zhou B. Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance. J Infect Public Health. 2020;13(1):68-74. doi:10.1016/j.jiph.2019.06.016

13. Colin PJ, Allegaert K, Thomson AH, et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Clin Pharmacokinet. 2019;58(6):767-780. doi:10.1007/s40262-018-0727-5

14. Deng C, Liu T, Zhou T, et al. Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis. Curr Pharm Des. 2013;51(05):407-415. doi:10.5414/CP201842

15. Dolton M, Xu H, Cheong E, et al. Vancomycin pharmacokinetics in patients with severe burn injuries. Burns. 2010;36(4):469-476. doi:10.1016/j.burns.2009.08.010

16. Dorajoo SR, Winata CL, Goh JHF, et al. Optimizing vancomycin dosing in chronic kidney disease by deriving and implementing a web-based tool using a population pharmacokinetics analysis. Front Pharmacol. 2019;10:641. doi:10.3389/fphar.2019.00641

17. Goti V, Chaturvedula A, Fossler MJ, Mok S, Jacob JT. Hospitalized patients with and without hemodialysis have markedly different vancomycin pharmacokinetics: a population pharmacokinetic model-based analysis. Ther Drug Monit. 2018;40(2):212-221. doi:10.1097/FTD.0000000000000490

18. Hughes MSA, Hughes JH, Endicott J, Langton M, Ahern JW, Keizer RJ. Developing parametric and nonparametric models for model-informed precision dosing: a quality improvement effort in vancomycin for patients with obesity. Ther Drug Monit. 2024;46(5):575-583. doi:10.1097/FTD.0000000000001214

19. Ji X, Ji S, He X, Zhu X, Chen R, Lu W. Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients. Acta Pharmacol Sin. 2018;39(2):286-293. doi:10.1038/aps.2017.57

20. Kim AJ, Lee JY, Choi SA, Shin WG. Comparison of the pharmacokinetics of vancomycin in neurosurgical and non-neurosurgical patients. Int J Antimicrob Agents. 2016;48(4):381-387. doi:10.1016/j.ijantimicag.2016.06.022

21. Nguyen VD, Côté A, Marsot A. External evaluation of longitudinal population pharmacokinetic models of vancomycin in patients with osteoarticular infections. Ther Drug Monit. 2025;47(4):520-528. doi:10.1097/FTD.0000000000001303

22. Kim D, Lee D, Ahn S, et al. A new population pharmacokinetic model for vancomycin in patients with variable renal function: Therapeutic drug monitoring based on extended covariate model using CKD-EPI estimation. J Clin Pharm Ther. 2019;44(5):750-759. doi:10.1111/jcpt.12995

23. Kim Y, Kim D, Kang G, Zang D, Lee DH. Pharmacokinetics of vancomycin in healthy Korean volunteers and Monte Carlo simulations to explore optimal dosage regimens in patients with normal renal function. Antibiotics. 2024;13(10):993. doi:10.3390/antibiotics13100993

24. Kovacevic T, Miljkovic B, Kovacevic P, et al. Population pharmacokinetic model of vancomycin based on therapeutic drug monitoring data in critically ill septic patients. J Crit Care. 2020;55:116-121. doi:10.1016/j.jcrc.2019.10.012

25. Le Blanc J, Projean D, Savignac S, et al. Toward model-based informed precision dosing of vancomycin in hematologic cancer patients: a first step. Clin Pharmacokinet. 2024;63(2):183-196. doi:10.1007/s40262-023-01329-0

26. Lin Z, Chen D, Zhu YW, et al. Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units. Sci Rep. 2021;11(1):2670. doi:10.1038/s41598-021-82312-2

27. Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther. 2006;31(5):447-454. doi:10.1111/j.1365-2710.2006.00762.x

28. Masich AM, Kalaria SN, Gonzalez J, et al. Pharmacokinetics of continuous-infusion vancomycin in critically ill patients. Pharmacotherapy. 2020;40(12):1261-1268. doi:10.1002/phar.2478

29. Medellín-Garibay SE, Ortiz-Martín B, Rueda-Naharro A, García B, Romano-Moreno S, Barcia E. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. J Antimicrob Chemother. 2016;71(2):471-479. doi:10.1093/jac/dkv372

30. Oda K, Matsumoto K, Shoji K, et al. Validation and development of population pharmacokinetic model of vancomycin using a real-world database from a nationwide free web application. J Infect Chemother. 2024;30(12):1244-1251. doi:10.1016/j.jiac.2024.05.014

31. Okada A, Kariya M, Irie K, et al. Population pharmacokinetics of vancomycin in patients undergoing allogeneic hematopoietic stem-cell transplantation. J Clin Pharmacol. 2018;58(9):1140-1149. doi:10.1002/jcph.1106

32. Parra-González D, Pérez-Mesa JA, Cuervo-Maldonado SI, et al. Pharmacokinetics of vancomycin among patients with chemotherapy-associated febrile neutropenia: which would be the best dosing to obtain appropriate exposure? Antibiotics. 2022;11(11):1523. doi:10.3390/antibiotics11111523

33. Revilla N, Martín-Suárez A, Pérez MP, González FM, Fernández de Gatta MDM. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol. 2010;70(2):201-212. doi:10.1111/j.1365-2125.2010.03679.x

34. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2011;55(6):2704-2709. doi:10.1128/AAC.01708-10

35. Smit C, Wasmann RE, Goulooze SC, et al. Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals. Br J Clin Pharmacol. 2020;86(2):303-317. doi:10.1111/bcp.14144

36. Staatz CE, Byrne C, Thomson AH. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. Br J Clin Pharmacol. 2006;61(2):164-176. doi:10.1111/j.1365-2125.2005.02547.x

37. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother. 2009;63(5):1050-1057. doi:10.1093/jac/dkp085

38. Tong DMH, Keizer RJ, Hughes JH. Improved prediction of vancomycin pharmacokinetics in patients receiving continuous renal replacement therapy using a novel population model validated with real-world data. Ther Drug Monit. Published online January 6, 2026. doi:10.1097/FTD.0000000000001432

39. Tsai YH, Yang YC, Ke SC, et al. Population pharmacokinetics of vancomycin in adults with no renal impairment. Antibiotics. 2024. doi:10.3390/antibiotics13010024

40. Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther. 2009;34(4):473-483. doi:10.1111/j.1365-2710.2008.01016.x

41. Zhang T, Krekels EHJ, Smit C, Van Dongen EPA, Brüggemann RJM, Knibbe CAJ. How to dose vancomycin in overweight and obese patients with varying renal (dys)function in the novel era of AUC 400–600 mg·h/L-targeted dosing. Clin Pharmacokinet. 2024;63(1):79-91. doi:10.1007/s40262-023-01324-5

42. Uster DW, Stocker SL, Carland JE, et al. A model averaging/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study. Clin Pharmacol Ther. 2021;109(1):175-183. doi:10.1002/cpt.2065. Erratum in: Clin Pharmacol Ther. 2021;110(5):1401. doi:10.1002/cpt.2353

43. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835-864. doi:10.1093/ajhp/zxaa036

44. Yu S, Visvanathan T, Field J, et al. Lean body mass: the development and validation of prediction equations in healthy adults. BMC Pharmacol Toxicol. 2013;14:53. doi:10.1186/2050-6511-14-53

45. Bertrand J, Mentré F. Mathematical Expressions of the Pharmacokinetic and Pharmacodynamic Models Implemented in the Monolix Software. INSERM U738, Paris Diderot University; 2008.

46. Johnson A, Bulgarelli L, Pollard T, et al. MIMIC-IV (version 3.1). PhysioNet; 2024. RRID:SCR_007345. doi:10.13026/kpb9-mt58